These results and findings that GHRH agonists, MR-356 or MR-409, reduced serum IGF-1 levels in nude mice xenografted with human NCI-N87 stomach cancer as well as in C57BL/6 mice show that the inhibitory effects occur also in vivo. The gene discussed is IGF1; the disease is gastric neoplasm.